Development of Immunotherapy & Cell Therapy

With the recent success of immunotherapy and cell therapy development in indications such as cancer, allergies and autoimmune diseases the need for appropriate, clinical grade peptide specifications has grown rapidly. Peptides have not only been used in passive immunotherapy approaches including adoptive cell transfer regimens but also in active immunotherapies relying on the application of dendritic cell based therapy concepts and peptide vaccines. To meet part of these requirements JPT has established an enhanced and tailored peptide production environment for such peptides and peptide pools that goes beyond its ISO 9001:2015 regulations. The benefits of using peptides as antigens apply even more to clinical applications in regard to the possibility to apply stringent quality controls.

Clinical Peptides for development of immunotherapy & cell therapy

JPT’s Clinical Peptides product lines GxP and ISO Plus are produced in production environments that are regulated by an enhanced ISO 9001:2015 quality management system for the stringent product requirements of immunotherapy as well as vaccine and drug development. Depending on the specifics of the immunotherapy concept to be applied, the resulting products have been shown to be applicable in clinical applications.

> Clinical Peptides Product Page

Develop cell and immunotherapies that apply peptides or peptide pools as antigens:

JPT’s peptides are for research use only and not intended for human in vivo application. JPT does not warrant that any peptides and peptide pools produced under GxP conditions are applicable in clinical applications (clinical grade peptides). JPT invites its customers to visit, inspect and audit our facilities to make an educated decision on whether or not peptides or peptide pools produced under GxP conditions are suited for a specific application.

Request a price
for Clinical Peptides

News Highlights

Quality Assurance

All production is performed according to ISO 9001:2015 standards

Stay in touch and be the first to receive the latest news!